Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Methacholine Challenge Test
Launched by MEDICAL UNIVERSITY OF WARSAW · Jan 15, 2015
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Bronchial hyperreactivity is defined as the increased respiratory tract responsiveness to multiple stimuli, which results in bronchial muscles constriction and bronchial lumen narrowing. Bronchial hyperreactivity is a hallmark of asthma, however it may also be present in other diseases, e.g. chronic obstructive pulmonary disease (COPD). Methacholine challenge test is one of the bronchial reactivity assessment methods. Methacholine acts directly on bronchial smooth muscles receptors and causes bronchoconstriction. Bronchial reactivity is increased in the presence of active inflammation. Meth...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • presence of asthma symptoms without confirmation of diagnosis by standard methods
- • dyspnea and/or cough of unknown etiology
- Exclusion Criteria:
- • FEV1 \<1.2 L or \<60% of predicted value
- • acute heart failure
- • myocardial infarction in last 3 months
- • transient ischaemic attack or stroke in last 3 months
- • aneurysms
- • methacholine allergy
- • pregnant and lactating women
- • administration of β2-mimetic, anticholinergic agent or theophylline before methacholine challenge test in 6, 8 and 24 hours, respectively
- • respiratory tract infection in last 6 weeks
- • patient inability to cooperate
About Medical University Of Warsaw
The Medical University of Warsaw is a leading academic institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to excellence in medical training and clinical practice, the university actively engages in a diverse range of clinical trials aimed at improving patient outcomes and enhancing medical knowledge. With a robust infrastructure and a multidisciplinary team of experts, the Medical University of Warsaw fosters collaboration in the development of novel therapies and interventions, contributing significantly to the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, Mazowieckie, Poland
Patients applied
Trial Officials
Tomasz A Urbankowski, MD
Principal Investigator
Department of Internal Medicine, Pneumonology and Allergy, Medical University of Warsaw
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials